Therapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course

Background. The use of atypical antipsychotics in schizophrenia contributes to the reduction of psychotic, affective, negative and cognitive disorders.Aims. To evaluate the effectiveness of ziprasidone therapy in patients with schizoaffective disorder and paranoid schizophrenia with episodic course....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	L. A. Ivanova, O. P. Vorsina, T. A. Eliseeva, K. A. Frolovа, E. V. Sapozhnikova
Formato:	article
Lenguaje:	RU
Publicado:	Scientific Сentre for Family Health and Human Reproduction Problems 2019
Materias:	schizoaffective disorder schizophrenia ziprasidone Science Q
Acceso en línea:	https://doaj.org/article/70ad0fb5d56344a5be659d884e219320
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:70ad0fb5d56344a5be659d884e219320
record_format	dspace
spelling	oai:doaj.org-article:70ad0fb5d56344a5be659d884e2193202021-11-23T06:14:42ZTherapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course2541-94202587-959610.29413/ABS.2019-4.2.14https://doaj.org/article/70ad0fb5d56344a5be659d884e2193202019-05-01T00:00:00Zhttps://www.actabiomedica.ru/jour/article/view/2052https://doaj.org/toc/2541-9420https://doaj.org/toc/2587-9596Background. The use of atypical antipsychotics in schizophrenia contributes to the reduction of psychotic, affective, negative and cognitive disorders.Aims. To evaluate the effectiveness of ziprasidone therapy in patients with schizoaffective disorder and paranoid schizophrenia with episodic course.Materials and methods. In accordance with ICD-10 there were 14 (63.6 %) people with schizoaffective disorder (F25), 8 (36.4 %) people with paranoid schizophrenia, episodic course (F20.x1). Treatment with ziprasidone lasted 42 days. The dose of ziprasidone in 6 patients (27.3 %) was 80 mg, in 10 patients (45.5 %) – 120 mg, in 6 patients (27.3 %) – 160 mg. Evaluation of the effectiveness of ziprasidone therapy was carried out using psychometric scales (PANSS, General clinical impression scale to assess the effectiveness of therapy – CGI-S, CGI-I), adverse events were registered with the UKU scale.Results. The number of respondents was 19 (86.3 %) (reduction of the total score on the PANSS scale > 20 % of the pre-treatment level). Ziprasidone was effective in patients with schizoaffective disorder with a significant decrease in total score on PANSS subscales to the 14 th day of therapy (p < 0.05), with paranoid schizophrenia with episodic course – by the 21st day (p < 0.01). According to the CGI-S scale at the end of therapy, “borderline condition” was observed in 10 patients (52.6 %), mild severity – in 3 (15.8 %), normal condition – in 6 (31.6 %). CGI-I scale showed a significant improvement in 10 patients (52.6 %), marked improvement – in 9 patients (47.4 %). Among the mild adverse events that do not require discontinuation of the drug, we noted: weakness – in 3 patients (15.8 %), drowsiness – in 3 (15.8 %), impaired concentration – in 2 (10.5 %), orthostatic dizziness – in 2 (10.5 %), galactorrhea – in 1 (5.3 %).Conclusions. Ziprasidone is an effective antipsychotic drug that has a safe tolerability profile. It can be used in patients with schizoaffective disorders and paranoid schizophrenia with episodic course.L. A. IvanovaO. P. VorsinaT. A. EliseevaK. A. FrolovаE. V. SapozhnikovaScientific Сentre for Family Health and Human Reproduction Problemsarticleschizoaffective disorderschizophreniaziprasidoneScienceQRUActa Biomedica Scientifica, Vol 4, Iss 2, Pp 101-105 (2019)
institution	DOAJ
collection	DOAJ
language	RU
topic	schizoaffective disorder schizophrenia ziprasidone Science Q
spellingShingle	schizoaffective disorder schizophrenia ziprasidone Science Q L. A. Ivanova O. P. Vorsina T. A. Eliseeva K. A. Frolovа E. V. Sapozhnikova Therapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course
description	Background. The use of atypical antipsychotics in schizophrenia contributes to the reduction of psychotic, affective, negative and cognitive disorders.Aims. To evaluate the effectiveness of ziprasidone therapy in patients with schizoaffective disorder and paranoid schizophrenia with episodic course.Materials and methods. In accordance with ICD-10 there were 14 (63.6 %) people with schizoaffective disorder (F25), 8 (36.4 %) people with paranoid schizophrenia, episodic course (F20.x1). Treatment with ziprasidone lasted 42 days. The dose of ziprasidone in 6 patients (27.3 %) was 80 mg, in 10 patients (45.5 %) – 120 mg, in 6 patients (27.3 %) – 160 mg. Evaluation of the effectiveness of ziprasidone therapy was carried out using psychometric scales (PANSS, General clinical impression scale to assess the effectiveness of therapy – CGI-S, CGI-I), adverse events were registered with the UKU scale.Results. The number of respondents was 19 (86.3 %) (reduction of the total score on the PANSS scale > 20 % of the pre-treatment level). Ziprasidone was effective in patients with schizoaffective disorder with a significant decrease in total score on PANSS subscales to the 14 th day of therapy (p < 0.05), with paranoid schizophrenia with episodic course – by the 21st day (p < 0.01). According to the CGI-S scale at the end of therapy, “borderline condition” was observed in 10 patients (52.6 %), mild severity – in 3 (15.8 %), normal condition – in 6 (31.6 %). CGI-I scale showed a significant improvement in 10 patients (52.6 %), marked improvement – in 9 patients (47.4 %). Among the mild adverse events that do not require discontinuation of the drug, we noted: weakness – in 3 patients (15.8 %), drowsiness – in 3 (15.8 %), impaired concentration – in 2 (10.5 %), orthostatic dizziness – in 2 (10.5 %), galactorrhea – in 1 (5.3 %).Conclusions. Ziprasidone is an effective antipsychotic drug that has a safe tolerability profile. It can be used in patients with schizoaffective disorders and paranoid schizophrenia with episodic course.
format	article
author	L. A. Ivanova O. P. Vorsina T. A. Eliseeva K. A. Frolovа E. V. Sapozhnikova
author_facet	L. A. Ivanova O. P. Vorsina T. A. Eliseeva K. A. Frolovа E. V. Sapozhnikova
author_sort	L. A. Ivanova
title	Therapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course
title_short	Therapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course
title_full	Therapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course
title_fullStr	Therapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course
title_full_unstemmed	Therapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course
title_sort	therapy of schizoaffective disorder and paranoid schizophrenia with episodic course
publisher	Scientific Сentre for Family Health and Human Reproduction Problems
publishDate	2019
url	https://doaj.org/article/70ad0fb5d56344a5be659d884e219320
work_keys_str_mv	AT laivanova therapyofschizoaffectivedisorderandparanoidschizophreniawithepisodiccourse AT opvorsina therapyofschizoaffectivedisorderandparanoidschizophreniawithepisodiccourse AT taeliseeva therapyofschizoaffectivedisorderandparanoidschizophreniawithepisodiccourse AT kafrolova therapyofschizoaffectivedisorderandparanoidschizophreniawithepisodiccourse AT evsapozhnikova therapyofschizoaffectivedisorderandparanoidschizophreniawithepisodiccourse
_version_	1718416950714957824

Therapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course

Ejemplares similares